Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$35.7 million.

  • TScan Therapeutics' Consolidated Net Income fell 1948.34% to -$35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.5 million, marking a year-over-year decrease of 2713.76%. This contributed to the annual value of -$126.4 million for FY2024, which is 4168.55% down from last year.
  • Per TScan Therapeutics' latest filing, its Consolidated Net Income stood at -$35.7 million for Q3 2025, which was down 1948.34% from -$37.0 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Consolidated Net Income high stood at -$7.9 million for Q1 2021, and its period low was -$37.0 million during Q2 2025.
  • Moreover, its 5-year median value for Consolidated Net Income was -$22.6 million (2023), whereas its average is -$23.0 million.
  • As far as peak fluctuations go, TScan Therapeutics' Consolidated Net Income plummeted by 12090.66% in 2021, and later plummeted by 256.33% in 2022.
  • TScan Therapeutics' Consolidated Net Income (Quarter) stood at -$14.2 million in 2021, then tumbled by 31.85% to -$18.7 million in 2022, then dropped by 4.75% to -$19.6 million in 2023, then tumbled by 77.02% to -$34.7 million in 2024, then fell by 2.85% to -$35.7 million in 2025.
  • Its Consolidated Net Income stands at -$35.7 million for Q3 2025, versus -$37.0 million for Q2 2025 and -$34.1 million for Q1 2025.